Highest-materiality recent filing
Viatris Q1 revenues $3.5B (+8% YoY), adj. EBITDA $1.0B, reaffirms FY guidance
Total revenues $3.5B, up 8% reported and 3% operational vs Q1 2025.
Viatris CFO Theodora Mistras to depart; Paul Campbell appointed interim CFO
Chief Financial Officer Theodora Mistras voluntarily ceases role effective May 8, 2026, to pursue another professional opportunity.
Viatris Q4 2025 revenue $3.7B, FY $14.3B; announces restructuring with $700-850M charges
Q4 total revenues $3.7B, FY2025 total revenues $14.3B; met or exceeded all 2025 guidance metrics.
Viatris to sell Biocon Biologics stake for $815M in cash and equity from Biocon Limited
Viatris receives $400M cash and $415M in newly issued Biocon Ltd shares for Biocon Biologics convertible preferred equity.
Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch
Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.
Viatris Q2 revenues beat expectations; reaffirms 2025 guidance, returns $630M+ to shareholders
Q2 total revenues exceeded company expectations; specific figures not disclosed.
Viatris reaffirms 2025 outlook after Q1 results; returns >$450M to shareholders YTD
Total revenues in Q1 2025 in line with expectations; three positive Phase 3 data readouts achieved.
FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.
Viatris shareholders reject say-on-pay proposal; approve 49M share increase for equity plan
Non-binding say-on-pay proposal failed with 49.23% in favor (458.9M against, 5.4M abstain).
Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt
Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.
Viatris launches cash tender offers for up to ~$1.8B in notes due 2025-2026
Any and all of $750M 1.650% Senior Notes due 2025 (Viatris) and €500M 2.125% Senior Notes due 2025 (Mylan) sought.
Viatris Q2: GAAP net loss $326M, adjusted EPS $0.69 up ~3%; raises new product revenue guidance
Total revenues $3.8B, operational growth ~2% on divestiture-adjusted basis; GAAP revenue declined ~3%
Viatris closes €1.95B divestiture of over-the-counter business to Cooper Consumer Health
Received €1.85B cash at closing (subject to adjustments) and up to €100M contingent additional consideration.
Viatris reports strong Q1: revenue $3.66B, adj. EPS $0.67, free cash flow $565M
Q1 revenue $3.66B, GAAP net earnings $113.9M; adjusted EBITDA $1.19B; GAAP EPS $0.09, adjusted EPS $0.67.
Viatris FY23 rev $15.4B, adj EBITDA $5.1B; 2024 guidance; $1B buyback boost; Idorsia deal
FY23 total revenues $15.4B, U.S. GAAP net earnings $54.7M, adjusted EBITDA $5.1B, free cash flow $2.4B.
On May 4, 2026, the Board of Directors of the Company (the “Board”) appointed Paul Campbell, Viatris’ current Chief Accounting Officer and Corporate Controller, to also serve as interim Chief Financial Officer of the Company, effective May 8, 2026, until a permanent Chief Financial Officer is appointed by the Board.
On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.
Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term
Rajiv Malik and Harry Korman each notified the Company of his intention to not stand for re-election at the 2025 Annual Meeting and to retire as a member of the Board at the end of his current term
On June 3, 2024, the Board of Directors (the “Board”) of Viatris Inc. (the “Company”) increased the number of directors on the Board from 11 to 12 and appointed Rogério Vivaldi Coelho, M.D., M.B.A. as an independent (as defined in the applicable NASDAQ listing rules) member of the Board with a term of office expiring at the Company’s 2024 annual meeting of shareholders and appointed him to the recently reestablished Science and Technology Committee of the Board, each appointment effective June 3, 2024.
Max materiality 0.85 · Median 0.62 · Most common event earnings